SELECT- The effect of Semaglutide on cardiovascular outcomes in people who are overweight or obese
Brief description of study
This study will demonstrate that semaglutide e weekly lowers the risk of cardiovascular events, in subjects with established CV disease and overweight or obesity in people 45 years or older .
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
cardiovascular overweight obese,Heart attack,Stroke,Overweight,Obese
-
Age: Between 45 Years - 99 Years
-
Gender: All
Heart attack Stroke Overweight Obese MALE AND FEMALE OVER AGE 45
Updated on
22 Jun 2022.
Study ID: 831615